Colgate-Palmolive (India) Limited has reported a 9% year-on-year increase in net sales to ₹1,583 crore for the quarter ended March 31, 2026, driven by domestic growth of 9.2%. The company’s gross margins remained strong at 69.6%, while EBITDA margins stood at a shade over 32% for the quarter. For the fiscal year ended March 31, 2026, the company recorded a net profit of ₹1,325.31 crore, a decrease from ₹1,436.81 crore in the previous year. Revenue from operations for the year stood at ₹6,035.04 crore, compared to ₹6,040.17 crore in FY25.

Financial Performance Summary

The Board of Directors has declared a second interim dividend of ₹24 per share, aggregating to ₹652.77 crore. This dividend will be paid on and from June 17, 2026. The company had previously declared a first interim dividend of ₹24 per share for the fiscal year, which was paid on and from November 19, 2025.

Strategic Highlights

Management highlighted a significant acceleration in net sales growth during the quarter, supported by broad-based growth across the Core and Premium portfolios, including Toothpaste, Toothbrush, and Personal Care. The company noted that its premiumization mix has increased by 35% over the past two years. Brand investments increased by 10% in absolute terms during the quarter, with a focus on premium sub-brands like Colgate Total and Colgate Visible White.

The company continues to invest in driving consumption through programs such as "Bright Smiles, Bright Future," which reached over 10 million children in 2025. Additionally, Colgate has partnered with state governments and the National Nursing Association to prioritize oral health education. The company’s execution capabilities remain robust, reaching 1.7 million outlets directly and adding 2 lakh more stores in 2025.

Regulatory Disclosures

The transcript of the analyst conference call held on May 22, 2026, was submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newspaper extracts of the audited financial results were published on May 23, 2026, in The Financial Express and Loksatta.

Five leading brokerages have issued a range of ratings on colgate palmolive , reflecting sharply divergent views on the company's near-term margin outlook and medium-term growth trajectory. Target prices span from ₹2025 to ₹2600, underscoring the varied assessments of risks and opportunities facing the oral care major. The divergence is driven by competing narratives — strong premiumization momentum and volume recovery on one hand, and mounting cost pressures from higher advertising spends, GST headwinds, and an inverted duty structure on the other.

Brokerage Ratings at a Glance

The following table summarizes the current stance of each brokerage, along with their respective target prices and key rationale:

Bearish Views: Margin Headwinds Take Centre Stage

Kotak Institutional Equities maintained its Reduce rating with a target price of ₹2025, acknowledging the company's strong 9% revenue growth driven by a balanced mix of volume and pricing gains. However, the brokerage flagged near-term EBITDA margin pressure stemming from gross margin decline, elevated advertising spends, and the impact of the inverted duty structure. Citi echoed a similarly cautious view, maintaining a Sell rating with a target price of ₹2050. While Citi recognized gradual recovery supported by premiumisation, improving urban demand, and a favorable base effect, it expects only a steady pace of volume recovery. The brokerage highlighted rising margin pressure from higher ad spends, GST headwinds, and intensifying competition as key concerns.

Bullish Outlook: Premiumization and Volume Revival Drive Optimism

Nomura took the most constructive stance among the five brokerages, upgrading Colgate Palmolive to Buy with a target price of ₹2500. The upgrade was anchored on normalization in core portfolio performance, strong premiumization trends, and a revival in volume growth to 4.5% in Q4. Nomura also cited expectations of near double-digit revenue growth in FY27, driven by mid-single-digit volume and pricing growth without demand backlash. Jefferies maintained its Buy rating with a target price of ₹2600 — the highest among the five — pointing to resilient core oral care demand and expectations of double-digit EPS growth in FY27. The brokerage noted that a favorable base after three weak years could renew investor interest, even as it acknowledged inconsistent revenue growth trends.

Neutral Stance: HSBC Sees Incremental Positives, Limited Re-rating

HSBC maintained a Hold rating with a target price of ₹2150, offering a balanced perspective. The brokerage noted that Q4 sales growth came in ahead of estimates, driven equally by volume and value contributions. It also highlighted positive traction in premium products, identifying premiumization as a long-term growth driver for the company. Despite a slight upgrade to its EBITDA estimates, HSBC saw limited change in the overall growth trajectory, suggesting the stock's near-term upside remains constrained.

Key Themes Across Brokerage Views

Across all five assessments, several common themes emerge:

• Premiumization is broadly recognized as a structural long-term growth lever
• Volume recovery is underway but its pace and sustainability remain debated
• Margin pressure from higher advertising spends and GST-related headwinds is a shared concern among bearish and neutral analysts
• FY27 outlook is a key differentiator, with bulls citing a favorable base and bears emphasizing structural cost challenges
• Q4 performance — including volume growth of 4.5% and sales ahead of estimates — is acknowledged across ratings as a positive data point

The wide dispersion in target prices and ratings reflects the complexity of Colgate Palmolive's investment case, balancing a resilient franchise and premiumization momentum against near-term profitability headwinds.